Clinical Trial

CVL Risk After Severe Glaucoma Surgery

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated November 26, 2025 completion). Its status may not reflect the trial's current state.
Summary
This retrospective cohort study analyzes risk factors for central visual loss (CVL) after severe-stage glaucoma surgery. The primary hypothesis is that 1) visual prognosis is determined primarily by early postoperative intraocular pressure (IOP) stability rather than surgical choice, and 2) the nature of risk (hypotony vs hypertension) is modified by baseline visual reserve. We analyzed outcomes in 523 patients with severe-stage glaucoma who underwent trabeculectomy or Ahmed glaucoma valve (AGV) implantation, focusing on the dichotomous risk profile stratified by baseline visual acuity.
Trial Details
NCT Number NCT07237555
Lead Sponsor Gangnam Severance Hospital
Conditions Severe-stage Glaucoma (Mean Deviation ≤ -20 dB)
Enrollment 523 participants
Start Date 2024-11-27
Primary Completion 2025-11-26 (estimated)
Study Completion 2026-11-26 (estimated)
Updated on ClinicalTrials.gov 2025-11-20